Does the media refer more to RAPP or CRNX?

In the previous week, Rapport Therapeutics had 10 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 13 mentions for Rapport Therapeutics and 3 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.17 beat Rapport Therapeutics' score of 0.78 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RAPP or LQDA?

In the previous week, Liquidia had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 14 mentions for Liquidia and 13 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.78 beat Liquidia's score of 0.56 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LNTH or RAPP?

In the previous week, Rapport Therapeutics had 5 more articles in the media than Lantheus. MarketBeat recorded 13 mentions for Rapport Therapeutics and 8 mentions for Lantheus. Lantheus' average media sentiment score of 1.32 beat Rapport Therapeutics' score of 0.78 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, RAPP or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is RAPP or BLTE more profitable?

Belite Bio's return on equity of -11.84% beat Rapport Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -29.02% -27.37% Belite Bio N/A -11.84% -11.62%

Does the media refer more to RAPP or BLTE?

In the previous week, Rapport Therapeutics had 9 more articles in the media than Belite Bio. MarketBeat recorded 13 mentions for Rapport Therapeutics and 4 mentions for Belite Bio. Rapport Therapeutics' average media sentiment score of 0.78 beat Belite Bio's score of -0.56 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Which has preferable earnings and valuation, DFTX or RAPP?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Rapport Therapeutics N/A N/A -$111.48M -$3.04 N/A

Is DFTX or RAPP more profitable?

Rapport Therapeutics' return on equity of -29.02% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Rapport Therapeutics N/A -29.02% -27.37%

Does the media favor DFTX or RAPP?

In the previous week, Rapport Therapeutics had 8 more articles in the media than Definium Therapeutics. MarketBeat recorded 13 mentions for Rapport Therapeutics and 5 mentions for Definium Therapeutics. Rapport Therapeutics' average media sentiment score of 0.78 beat Definium Therapeutics' score of 0.71 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rapport Therapeutics (RAPP) Competitors

$49.83 +0.50 (+1.01%)

As of 12:00 PM Eastern

Compare

RAPP vs. CRNX, LQDA, LNTH, BLTE, and DFTX

Should you buy Rapport Therapeutics stock or one of its competitors? Rapport Therapeutics's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Rapport Therapeutics compare to Crinetics Pharmaceuticals?

Rapport Therapeutics (NASDAQ:RAPP) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Rapport Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

In the previous week, Rapport Therapeutics had 10 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 13 mentions for Rapport Therapeutics and 3 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.17 beat Rapport Therapeutics' score of 0.78 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics presently has a consensus target price of $62.86, suggesting a potential upside of 26.14%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 4.49%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Rapport Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rapport Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Rapport Therapeutics' return on equity of -29.02% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Rapport Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Crinetics Pharmaceuticals	$7.70M	1,168.30	-$465.32M	-$5.04	N/A

Summary

Rapport Therapeutics beats Crinetics Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Liquidia?

Rapport Therapeutics (NASDAQ:RAPP) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

64.5% of Liquidia shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rapport Therapeutics presently has a consensus target price of $62.86, indicating a potential upside of 26.14%. Liquidia has a consensus target price of $98.08, indicating a potential upside of 38.64%. Given Liquidia's higher probable upside, analysts clearly believe Liquidia is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Rapport Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Rapport Therapeutics' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Liquidia	30.74%	149.65%	36.30%

In the previous week, Liquidia had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 14 mentions for Liquidia and 13 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.78 beat Liquidia's score of 0.56 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Liquidia	$158.32M	40.00	-$68.92M	$1.37	51.64

Summary

Liquidia beats Rapport Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Rapport Therapeutics (NASDAQ:RAPP) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Lantheus presently has a consensus target price of $108.11, suggesting a potential upside of 7.01%. Rapport Therapeutics has a consensus target price of $62.86, suggesting a potential upside of 26.14%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Rapport Therapeutics had 5 more articles in the media than Lantheus. MarketBeat recorded 13 mentions for Rapport Therapeutics and 8 mentions for Lantheus. Lantheus' average media sentiment score of 1.32 beat Rapport Therapeutics' score of 0.78 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 17.69% compared to Rapport Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Lantheus has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.28	$233.56M	$4.14	24.40
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Summary

Lantheus beats Rapport Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Rapport Therapeutics compare to Belite Bio?

Rapport Therapeutics (NASDAQ:RAPP) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market.

In the previous week, Rapport Therapeutics had 9 more articles in the media than Belite Bio. MarketBeat recorded 13 mentions for Rapport Therapeutics and 4 mentions for Belite Bio. Rapport Therapeutics' average media sentiment score of 0.78 beat Belite Bio's score of -0.56 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Belite Bio's return on equity of -11.84% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-29.02%	-27.37%
Belite Bio	N/A	-11.84%	-11.62%

Belite Bio is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

Rapport Therapeutics currently has a consensus target price of $62.86, indicating a potential upside of 26.14%. Belite Bio has a consensus target price of $205.80, indicating a potential upside of 26.02%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Rapport Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

0.5% of Belite Bio shares are owned by institutional investors. 12.5% of Rapport Therapeutics shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Rapport Therapeutics beats Belite Bio on 8 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Rapport Therapeutics (NASDAQ:RAPP) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

27.9% of Definium Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$3.04	N/A

In the previous week, Rapport Therapeutics had 8 more articles in the media than Definium Therapeutics. MarketBeat recorded 13 mentions for Rapport Therapeutics and 5 mentions for Definium Therapeutics. Rapport Therapeutics' average media sentiment score of 0.78 beat Definium Therapeutics' score of 0.71 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics presently has a consensus price target of $63.00, suggesting a potential upside of 39.78%. Rapport Therapeutics has a consensus price target of $62.86, suggesting a potential upside of 26.14%. Given Definium Therapeutics' higher possible upside, research analysts clearly believe Definium Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rapport Therapeutics' return on equity of -29.02% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Rapport Therapeutics	N/A	-29.02%	-27.37%

Summary

Rapport Therapeutics beats Definium Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.39B	$12.56B	$7.33B	$12.76B
Dividend Yield	N/A	2.61%	2.54%	10.78%
P/E Ratio	-16.40	778.09	271.19	24.20
Price / Sales	N/A	957.62	696.19	128.00
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	4.90	10.51	11.31	6.52
Net Income	-$111.48M	$2.79B	$3.45B	$347.63M
7 Day Performance	1.67%	2.70%	2.87%	1.57%
1 Month Performance	22.49%	5.58%	8.59%	5.22%
1 Year Performance	240.60%	8.62%	27.52%	17.83%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	3.6916 of 5 stars	$49.83 +1.0%	$62.86 +26.1%	+234.0%	$2.39B	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	1.946 of 5 stars	$84.72 0.0%	$81.00 -4.4%	+174.2%	$8.99B	$42.16M	N/A	210	Positive News
LQDA Liquidia	4.3916 of 5 stars	$74.33 -4.3%	$98.08 +32.0%	+161.8%	$6.65B	$450.91M	54.26	50
LNTH Lantheus	3.4802 of 5 stars	$100.26 -0.6%	$108.11 +7.8%	+73.2%	$6.54B	$1.54B	24.22	1,193	Positive News High Trading Volume
BLTE Belite Bio	3.2309 of 5 stars	$162.57 -0.4%	$205.80 +26.6%	+146.7%	$6.52B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. CRNX, LQDA, LNTH, BLTE, and DFTX

How does Rapport Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Rapport Therapeutics compare to Liquidia?

Summary

How does Rapport Therapeutics compare to Lantheus?

Summary

How does Rapport Therapeutics compare to Belite Bio?

Summary

How does Rapport Therapeutics compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. CRNX, LQDA, LNTH, BLTE, and DFTX

How does Rapport Therapeutics compare to Crinetics Pharmaceuticals?

Which has more volatility and risk, RAPP or CRNX?

Does the media refer more to RAPP or CRNX?

Do analysts rate RAPP or CRNX?

Do institutionals and insiders believe in RAPP or CRNX?

Is RAPP or CRNX more profitable?

Which has preferable earnings and valuation, RAPP or CRNX?

Summary

How does Rapport Therapeutics compare to Liquidia?

Do insiders & institutionals have more ownership in RAPP or LQDA?

Do analysts prefer RAPP or LQDA?

Which has more risk & volatility, RAPP or LQDA?

Is RAPP or LQDA more profitable?

Does the media refer more to RAPP or LQDA?

Which has stronger valuation and earnings, RAPP or LQDA?

Summary

How does Rapport Therapeutics compare to Lantheus?

Do analysts rate LNTH or RAPP?

Do insiders and institutionals hold more shares of LNTH or RAPP?

Does the media favor LNTH or RAPP?

Is LNTH or RAPP more profitable?

Which has higher earnings & valuation, LNTH or RAPP?

Which has more volatility & risk, LNTH or RAPP?

Summary

How does Rapport Therapeutics compare to Belite Bio?

Which has more risk & volatility, RAPP or BLTE?

Does the media refer more to RAPP or BLTE?

Is RAPP or BLTE more profitable?

Which has stronger earnings and valuation, RAPP or BLTE?

Do analysts recommend RAPP or BLTE?

Do insiders and institutionals believe in RAPP or BLTE?

Summary

How does Rapport Therapeutics compare to Definium Therapeutics?

Which has more volatility and risk, DFTX or RAPP?

Do institutionals & insiders hold more shares of DFTX or RAPP?

Which has preferable earnings and valuation, DFTX or RAPP?

Does the media favor DFTX or RAPP?

Do analysts prefer DFTX or RAPP?

Is DFTX or RAPP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools